pharmaceutical anti counterfeiting technologies 2014-2024
DESCRIPTION
For an Executive Summary of this report please contact [email protected] (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1154/Pharmaceutical-Anti-counterfeiting-Technologies-Market-Analysis-2014-2024TRANSCRIPT
©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis
2014-2024
www.visiongain.com
Contents
1.1 Market Highlights
1.2 Overview of the Report Content
1.3 Research and Analysis Methods
1.4 Glossary of Terms Related to Pharmaceutical Anti-counterfeiting Technologies
2.1 Drug Counterfeiting: A Thorn in the Side of the Pharma Industry
2.1.1 Regional Differences Hindering Information Exchange
2.1.2 Rising Counterfeiting Incidents in Developed Regions
2.2 The Most Commonly Counterfeited Drugs
2.3 Types of Counterfeit Drugs
2.3.1 Substandard Pharmaceutical Products as Counterfeits
2.3.2 Global Outsourcing of Active Pharmaceutical Ingredients (APIs)
2.3.2.1 Heparin Contamination
2.3.2.2 Stricter Enforcement needed for API Control
2.4 Why are Drugs Counterfeited?
2.4.1 Methods of Producing Pharmaceutical Counterfeits
2.4.2 Moving Counterfeits into the Pharmaceutical Supply Chain
2.4.3 Corruption Within the Pharmaceutical Distribution System
2.5 The Internet and its Role in Pharmaceutical Counterfeiting
2.5.1 Online Pharmacies: A Cheap Distribution System for Pharma Counterfeits
2.5.2 Legal Online Pharmacies: A Convenient and Quick Way of Dispensing Medication
2.5.3 Verifying the Authenticity of Online Pharmacies
2.6 Pharmaceutical Counterfeiting: The Global Costs
2.6.1 The Impact of Pharmaceutical Counterfeiting on Consumers
2.6.2 The Impact of Counterfeiting on Healthcare Providers
2.6.3 The Impact of Counterfeiting on Pharma Manufacturers
1. Executive Summary
2. Introduction to Pharmaceutical Counterfeiting
www.visiongain.com
Contents 2.6.4 The Impact of Pharmaceutical Counterfeiting on Governments
2.6.5 The Impact of Counterfeiting on the Global Pharmaceutical Industry
2.6.5.1 Operation Pangea: Europol’s Fight Against Counterfeiting
2.6.5.2 Legislative Deficiencies Aiding Counterfeiting Operations
2.7 Factors Fuelling Pharmaceutical Counterfeiting
2.7.1 An Erratic Supply or Shortage of Drugs Promotes Counterfeiting
2.7.2 Price Differentials and High Price Medicines Drive People to Cheaper Counterfeit
Alternatives
2.7.3 Drug Misuse Creates a Market for Counterfeiting
2.7.4 Trade through Free-Trade Zones/Free Ports Is an Important Route for Counterfeiters
2.7.5 The Trade of Pharmaceuticals through Several Intermediaries Helps Hide Counterfeit
Drugs
2.7.6 Counterfeiters Target Developed Markets
2.7.7 Parallel Trade – a Counterfeiting Route in Europe
3.1 Passive Technologies
3.1.1 Security Inks as Anti-counterfeiting Technologies
3.1.2 Holograms as Anti-counterfeiting Technologies
3.1.3 Visual Inspection as the First Line of Defence Against Drug Counterfeiting
3.1.4 Overt and Hidden Imaging
3.2 Active Technologies
3.2.1 Electromagnetic Tags – Radio Frequency Identification (RFID) as Anti-counterfeiting
Technologies
3.2.2 Taggants as Anti-counterfeiting Technologies
3.2.3 Mass Encoding Technology
3.2.3.1 Digital Mass Serialisation Technology (DMS)
3.2.3.2 Digital Mass Encryption (DME)
3.2.3.3 Barcode Applications: Serialisation is Key
3. Leading Technologies and Applications
www.visiongain.com
Contents
4.1 3M: A Diversified Technology Multinational
4.2 Alien Technology: RFID Technology Specialist
4.3 AlpVision: Cryptoglyph Security Solution
4.3.1 Fingerprint: A ‘Read Only’ Technology
4.3.2 Krypsos Platform
4.3.3 Cryptoglyph
4.3.4 AlpVision: Integration of Phone Applications Important for Future Growth
4.4 Angstrom Technologies – Security Inks
4.5 Authentix: Product Authentication and Brand Protection
4.5.1 Product-specific Track-and-Trace Solutions
4.5.2 Packaging Solutions
4.6 Avery Dennison: RFID Technologies Expert
4.7 Colorcon
4.7.1 Colorcon’s Taggants: On-Dose ID
4.7.2 Colorcon’s Brand Enhancement Service
4.8 Chesapeake: Acquired by The Caryle Group
4.9 Covectra
4.9.1 Covectra’s Authenti-Track System for Product Tracing
4.9.2 Covectra’s ControlTrack System for Combating Opioid Drug Diversion
4.10 Everest Holovisions
4.11 InkSure Technologies: Leader in Cloud-based Authentication
4.12 Intermec: A Workflow Performance Company
4.12.1 Automatic Information Data Capture
4.12.2 Will Recent Acquisitions Spell an Uncertain Future?
4.13 NanoGuardian
4.13.1 NanoCodes: Data Carriers of Limitless Potential
4. Leading Companies in the Pharmaceutical Anti-counterfeiting
Technologies Market
www.visiongain.com
Contents 4.13.2 NanoGuardian’s Global Licensing Agreement with Capsugel
4.13.3 The Closed-Loop Protection System
4.13.4 Major Players Showing Interest In NanoGuardian’s Technologies
4.14 ThermoFisher Scientific
4.14.1 Acquisition of Ahura Scientific
4.14.2 Continous Growth and Expansion into Emerging Markets
4.14.3 ThermoFisher Scientific’s TruScan Technology
4.15 TruTag Technologies
4.15.1 TruTag’s Silica Microtag Technology
4.16 UPM Raflatac
4.17 Zebra Technologies
5.1 Pharmaceutical Anti-counterfeiting Technologies: Market Overview
5.1.1 Size of the Pharmaceutical Anti-counterfeiting Technologies Market in 2012 and
2013
5.1.2 Global Pharmaceutical Anti-counterfeiting Technologies Market: Growth Trends
5.1.3 Global Pharmaceutical Anti-counterfeiting Technologies Market Forecast 2012-2017
5.1.4 Global Pharmaceutical Anti-counterfeiting Technologies Market Forecast 2017-2024
5.1.5 Changing Market Shares by Sector, 2012-2024
5.2 Pharmaceutical RFID Market Forecast 2012-2024
5.3 Pharmaceutical Security Printing Market Forecast 2012-2024
5.4 Pharmaceutical Taggants Market Forecast 2012-2024
5.5 Pharmaceutical Hologram/OVD Market Forecast 2012-2024
5.6 Other Pharmaceutical Anti-counterfeiting Technologies Market Forecast 2012-2024
5. Global Pharmaceutical Anti-counterfeiting Technologies Market
2014-2024
www.visiongain.com
Contents
6.1 Pharmaceutical Counterfeiting: A Global Conundrum
6.1.1 How Will National Market Shares Change to 2024?
6.2 Regional Pharmaceutical Anti-counterfeiting Market Forecast, 2014-2024
6.2.1 The US Market
6.2.2 EU5: Europe’s Leading Anti-counterfeiting Technology Markets
6.2.3 Japan: Uptake of Key Technologies Important for Market Growth
6.2.4 China: Set to See High Growth Rates Continue Until 2017
6.2.5 India: New Mandates will Help Deter Counterfeiters
6.2.5.1 Collaboration with the WHO will Help Regain Consumer Confidence in
Pharma Products
6.2.6 Brazil: South America’s Largest Pharmaceutical Market
6.2.7 Russia: Highest Per-Capita Spending on Healthcare of All the BRIC Nations
7.1 SWOT Analysis of the Pharmaceutical Anti-counterfeiting Technologies Market, 2014-2024
7.2 Strengths
7.2.1 Growing Interest from Pharmaceutical Companies in Tackling Counterfeiting
7.2.1.1 AstraZeneca
7.2.1.2 GlaxoSmithKline
7.2.1.3 Johnson & Johnson
7.2.1.4 Novartis
7.2.1.5 Pfizer
7.2.1.6 Sanofi
7.2.2 Organisations Promoting the Awareness and Implementation of Anti-Counterfeiting
Solutions
6. Leading National Markets 2014-2024
7. Issues Affecting the Pharmaceutical Anti-counterfeiting
Technologies Market
www.visiongain.com
Contents 7.2.2.1 Anti-counterfeiting and Product Protection Programme (A-CAPPP)
7.2.2.2 Anti-counterfeiting Group (ACG)
7.2.2.3 Brazil’s National Health Surveillance Agency (ANVISA)
7.2.2.4 Canadian Anti-counterfeiting Network (CACN)
7.2.2.5 Center for Healthcare Supply Chain Research
7.2.2.6 European Alliance for Access to Safe Medicines (EAASM)
7.2.2.7 European Federation of Pharmaceutical Industries and Associations (EFPIA)
7.2.2.8 International Anti-counterfeiting Coalition (IACC)
7.2.2.9 International Authentication Association (IAA)
7.2.2.10 The Pharmaceutical Security Institute (PSI)
7.2.3 Track-and-Trace Solutions Boosting Supply Chain Efficiency
7.2.4 New Technologies Providing More Comprehesive Anti-Counterfeiting Protection
7.2.5 Litigation Proceedings over Counterfeit Products Affecting Profitability
7.3 Weaknesses
7.3.1 The Lack of Standardisation Across the Industry as a Whole Will Impede Technology
Adoption
7.3.2. Insufficient Quantitative Measurement of the Effectiveness of Anti-counterfeiting
Technologies
7.3.2.1 Complexity of Factors Influencing Drug Revenue Makes Quantifying
Commercial Impact of Anti-counterfeiting Technologies Difficult
7.3.3 Technology Reliability and the Ease of Integration into Manufacturing Processes
7.3.4 Lack of Cooperation Between Various Governmental Organisations Aids Drug
Counterfeiters
7.4 Opportunities
7.4.1 Constantly Evolving Technologies Allows for Product Innovation
7.4.2 Anti-counterfeiting Technologies for the Prevention of Online Fraud
7.5 Threats
7.5.1 The High Volume of Counterfeiting Activities Could Devalue Anti-counterfeiting
Solutions
7.5.2 Developing Countries Lack Infrastructure to Effectively Deal with Counterfeiting
7.5.3 Pace of Innovation May Not Keep up with the Counterfeiters
www.visiongain.com
Contents 7.6 STEP Analysis of the Pharmaceutical Anti-counterfeiting Technologies Market, 2014-2024
7.6.1 Social Factors
7.6.1.1 The Weak Enforcement of Legislation
7.6.1.2 Corruption: A Hindrance to Eradicating Pharmaceutical Counterfeiting
7.6.1.3 Changing Public Perception and Consumer Education
7.6.1.4 Concerns Over Information Privacy
7.6.2 Technological Factors
7.6.2.1 Smartphone Read and Verify: A Customer Empowerment Tool
7.6.2.2 US FDA’s Counterfeit Detection Device
7.6.2.3 UV and IR Inks Being Used Covertly for Increased Security
7.6.2.4 Bokode: A Potential Replacement for Barcodes?
7.6.2.5 SigNature DNA
7.6.3 Economic Factors
7.6.3.1 Implementation Costs of Anti-counterfeiting Technologies
7.6.3.2 Anti-counterfeiting Technologies Require R&D Investment
7.6.4 Political Factors
7.6.4.1 World Health Organization: The IMPACT Programme
7.6.4.2 Anti-Counterfeiting Trade Agreement (ACTA)
7.6.4.3 The Fagan Civil Case: Effects of Litigation on Players in the Drug Supply
Chain
7.6.4.4 Legislations for Supply Chain Security
7.6.4.5 E-pedigree: A Catalyst for Product Serialisation
7.6.4.5.1 E-pedigree: Challenges Involved in Implementation
7.6.4.5.2 EU and the US: Differing Supply Chain Authentication
7.6.4.6 UK MHRA: Falsified Medical Products Strategy
7.6.4.7 The EU’s Falsified Medicines Directive
8.1 Interview with Dr Fred Jordan, Chief Executive Officer, AlpVision
8. Expert Opinions
www.visiongain.com
Contents 8.1.1 Current State of Counterfeiting in the Pharmaceutical Industry
8.1.2 AlpVison’s Key Technologies and Strategies for Combating Counterfeiters
8.1.3 The Future of Anti-counterfeiting Technologies
8.1.4 On Whom do the Responsibilities for Counterfeiting Prevention Lie?
8.1.5 The Major Barriers Facing Implementation of Anti-counterfeiting Technologies
8.1.6 Future Growth Drivers of the Anti-counterfeiting Technologies Market
8.2 Interview with a Spokesperson from a Leading Anti-counterfeiting Technologies Company
Based in the US.
8.2.1 On the Threats Posed by Counterfeit Products
8.2.2 Keeping Up with the Counterfeiters: An Impossible Task?
8.2.3 Duty of Care
8.2.4 DNA Technology: The Innovation Needed to Defeat Counterfeiting?
8.2.5 Future Prospects of the Pharma Anti-counterfeiting Industry
9.1 The Pharmaceutical Anti-counterfeiting Technologies Industry 2014-2024
9.2 Government Mandates Will Fuel Growth in the Market
9.3 The US Will Continue to Dominate the Market
9.4 New Directives Will Ensure Track-and-Trace Market Leadership
9.5 European Preference for Mandated 2D Barcode Technology
9.6 Improved Regulation of Online Pharmacies Necessary for Anti-counterfeiting Technologies to
be Effective
9.7 Market Expansion Will be Dependent on the Development of Industry-Wide Standards for the
Use of the Available Technologies
9. Conclusion
www.visiongain.com
Contents
Table 2.1 Global Reported Incidents of Drug Counterfeiting, 2008-2012
Table 2.2 Classification of Counterfeit Pharmaceutical Products
Table 3.1 Anti-counterfeiting Technologies Used in the Pharmaceutical Industry
Table 3.2 Leading Anti-counterfeiting Security Ink Manufacturers, 2013
Table 3.3 Leading Anti-counterfeiting Holographic Labelling Manufacturers, 2013
Table 3.4 Leading Radio Frequency Identification (RFID) System Manufacturers, 2013
Table 3.5 Leading Pharmaceutical Taggants Manufacturers, 2013
Table 4.1 3M: Revenue ($m) and Revenue Shares (%) by Business Segment, 2012
Table 4.2 Alien Technologies: Types of RFID Readers Produced, 2013
Table 4.3 AlpVision: Products and Applications, 2013
Table 4.4 Angstrom Technologies: Products and Applications, 2013
Table 4.5 Avery Dennison: Revenue ($m) and Revenue Shares (%) by Business Segment, 2012
Table 4.6 Avery Dennison: RFID Products for Use in Pharmaceuticals, 2013
Table 4.7 Colorcon: Product Groups, Sub-groups, and Examples 2013
Table 4.8 Everest Holovision: Products and Applications, 2013
Table 4.9 InkSure Technologies: Products and Applications, 2013
Table 4.10 InkSure Technologies: Historical Revenue ($m, AGR %) 2009-2012
Table 4.11 Intermec: Product Lines and Descriptions, 2013
Table 4.12 Intermec: Historical Revenue ($m, AGR %) 2009-2012
Table 4.13 ThermoFisher Scientific: Historical Revenue ($bn) 2009-2012
Table 4.14 ThermoFisher Scientific: Revenue Shares (%) by Region, 2012
Table 4.15 UPM Raflatac: Product Groups and Descriptions, 2013
Table 4.16 Zebra Technologies: Product Groups and Descriptions, 2013
Table 4.17 Zebra Technologies: Historical Revenue ($m, AGR%) 2009-2012
Table 5.1 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenues ($m) and
Market Shares (%) by Sector, 2012
Table 5.2 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenue Forecast
($m, AGR%, CAGR%) by Sector, 2012-2017
Table 5.3 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenue Forecast
List of Tables
www.visiongain.com
Contents ($m, AGR%, CAGR%) by Sector, 2017-2024
Table 5.4 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenue ($m) by
Sector, 2012, 2017, 2024
Table 5.5 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Sector, 2012, 2017, 2024
Table 5.6 RFID: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 5.7 Security Printing: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 5.8 Pharmaceutical Taggants: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 5.9 Holograms/OVD: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 5.10 Other Technologies: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
Table 6.1 The Global Pharmaceutical Anti-counterfeiting Technologies: Revenue Forecast ($m,
AGR%, CAGR%) by Region, 2012-2017
Table 6.2 The Global Pharmaceutical Anti-counterfeiting Technologies: Revenue Forecast ($m,
AGR%, CAGR%) by Region, 2017-2024
Table 6.3 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Region, 2012, 2017, 2024
Table 6.4 US Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%, CAGR%),
2012-2024
Table 6.5 EU5 Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%, CAGR%),
2012-2024
Table 6.6 Japanese Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 6.7 Chinese Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 6.8 Indian Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 6.9 Brazilian Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 6.10 Russian Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m, AGR%,
CAGR%), 2012-2024
Table 7.1 SWOT Analysis of the Pharmaceutical Anti-counterfeiting Technologies Industry, 2014-
www.visiongain.com
Contents 2024
Table 7.2 Selected Instances of Counterfeiting Activities, 2012-2013
Table 7.3 Selected Instances of Counterfeiting Activities, 2009-2011
Table 7.4 STEP Analysis for the Pharmaceutical Anti-counterfeiting Technologies Industry, 2014-
2024
www.visiongain.com
Contents
Figure 2.1 Global Reported Incidents of Drug Counterfeiting, 2008-2012
Figure 2.2 Flow Chart of the Route Taken by Counterfeit Pharma Products Entering the Legal
Supply Chain
Figure 3.1 Holograms Anti-counterfeiting Technologies: Drivers and Restraints, 2014-2024
Figure 3.2 Basic Components of a RFID System
Figure 3.3 RFID Anti-counterfeiting Technologies: Drivers and Restraints, 2014-2024
Figure 3.4 Taggants Anti-counterfeiting Technologies: Drivers and Restraints, 2014-2024
Figure 3.5 Barcode Anti-counterfeiting Technologies: Drivers and Restraints, 2014-2024
Figure 4.1 3M: Revenue Shares (%) by Business Segment, 2012
Figure 4.2 Authentix’s Global Monitoring Service: A Three Step Program
Figure 4.3 Avery Dennison: Revenue Shares (%) by Business Segment, 2012
Figure 4.4 InkSure Technologies: Historical Revenue ($m) 2009-2012
Figure 4.5 Intermec: Historical Revenue ($m) 2009-2012
Figure 4.6 ThermoFisher Scientific: Historical Revenue ($bn) 2009-2012
Figure 4.7 ThermoFisher Scientific: Revenue Shares (%) by Region, 2012
Figure 4.8 Zebra Technologies: Historical Revenue ($m) 2009-2012
Figure 5.1 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenues ($m) by
Sector, 2012
Figure 5.2 The Global Pharmaceutical Anti-counterfeiting Technologies: Revenue Forecast ($m),
2012- 2017
Figure 5.3 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenue Forecast
($m), 2017-2024
Figure 5.4 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Revenue ($m) by
Sector, 2012, 2017, 2024
Figure 5.5 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Sector, 2012
Figure 5.6 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Sector, 2017
Figure 5.7 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
List of Figures
www.visiongain.com
Contents by Sector, 2024
Figure 5.8 RFID: Revenue Forecast ($m), 2012-2024
Figure 5.9 Security Printing: Revenue Forecast ($m), 2012-2024
Figure 5.10 Pharmaceutical Taggants: Revenue Forecast ($m), 2012-2024
Figure 5.11 Holograms/OVD: Revenue Forecast ($m), 2012-2024
Figure 5.12 Other Technologies Revenue Forecast ($m), 2012-2024
Figure 6.1 US and EU5 Pharmaceutical Anti-counterfeiting Technologies: Revenue Forecast ($m),
2012-2024
Figure 6.2 China, India, Brazil and Russia Pharmaceutical Anti-counterfeiting Technologies Market:
Revenue Forecast ($m), 2012-2024
Figure 6.3 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Region, 2012
Figure 6.4 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Region, 2017
Figure 6.5 The Global Pharmaceutical Anti-counterfeiting Technologies Market: Market Shares (%)
by Region, 2024
Figure 6.6 US Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-2024
Figure 6.7 EU5 Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-2024
Figure 6.8 Japanese Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-
2024
Figure 6.9 Chinese Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-2024
Figure 6.10 Indian Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-2024
Figure 6.11 Brazilian Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-
2024
Figure 6.12 Russian Pharmaceutical Anti-counterfeiting Market: Revenue Forecast ($m), 2012-2024
Figure 7.1 EU Supply Chain Authentication Strategy, 2013
Figure 7.2 US Supply Chain Authentication Strategy, 2013
Figure 9.1 Global Pharmaceutical Anti-counterfeiting Market: RFID, Security Printing,
Holograms/OVD, and Taggants Revenue Forecast ($m), 2012-2024
www.visiongain.com
Contents
3M
Adhesives Research
Ahura Scientific
Alien Technologies
AlpVision
Altegrity Risk International
American Academy of Pediatrics (AAP)
American Express
AmerisourceBergen
Angstrom Technologies
Anti-Counterfeiting and Product Protection Programme (A-CAPPP)
Anti-Counterfeiting Group (ACG)
Apoteket
Applied DNA Sciences
ARmark Authentication Technologies LLC
AstraZeneca
Australian Therapeutic Goods Administration (TGA)
Authentix
Automation
Avery Dennison
Axway
Baxter
Canadian Anti-Counterfeiting Network (CACN)
Capsugel
Cellular Bioengineering Inc.
Center for Healthcare Supply Chain Research
Center for Medicine in the Public Interest (US)
CFC International
Organisations Mentioned in this Report
www.visiongain.com
Contents Chesapeake
Colorcon
Cortegra
Covectra
Digital China
Directorate General of Foreign Trade [India]
Domino
Drugs Standard Control Organisation
DuPont
European Alliance for Access to Safe Medicines (EAASM)
European Commission
European Directorate for the Quality of Medicines and Healthcare (EDQM),
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Medicines Agency
Europol
Everest Holovisions
GlaxoSmithKline (GSK)
Healthcare Distribution Management Association (HDMA)
Heart UK
Hologram Industries
Holomex
HOMAI (hologram manufactures association of India)
Honeywell International
Image Solutions
Impinj Inc
Ingenia Technology
InkSure Technologies
Intermec/ Interface Mechanisms
International Anti-counterfeiting Association (IAA)
www.visiongain.com
Contents International Anti-Counterfeiting Coalition (IACC)
International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
International Ink Company
International Medical Products Anti-Counterfeiting Taskforce (IMPACT)
International Policy Network
Interpol
Japanese Pharmaceutical Manufacturers Association (JPMA)
Johnson & Johnson
Kodak
Loughborough University
LaserLock
Massachusetts Institute of Technology (MIT)
MasterCard
Medicines and Healthcare products Regulatory Agency (MHRA)
Medicrime Convention Council
Menasha Corporation
MicroTag Temed Ltd
Microtrace Solutions
Motorola
NanoGuardian
NanoInk Inc.
Nanotech Security Corp.
National Agency for Food and Drug Administration and Control (NAFDAC) [Nigeria]
National Association of Boards of Pharmacy (NABP)
National Health Surveillance Agency (ANVISA)
Neri Labels
Novartis
Novavision
OEP Technologie BV
One Equity Partners
OpSec Security
www.visiongain.com
Contents Organisation for Economic Co-operation and Development (OECD)
Pacific Holographics
Paralec Inc
Partner for Safe Medicines (PSM) India
Pera Innovations
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
PharmaSecure
Quality Brands Protection Committee (QBPC) [China]
Reckitt Benckiser
Roche
Royal Pharmaceutical Society of Great Britain (RPSGB)
Sanofi
Savi Technology
ScanSource
Scientific Protein Laboratories (SPL)
SICPA
Siemens
Smartrac
South Dakota School of Mines and Technology
State Food and Drug Administration (SFDA) [China]
Sun Chemical
Symbol Technologies
Systech
Tagsys RFID
Teva Pharmaceuticals
Texas Instruments
The Caryle Group
The International Hologram Manufacturers Association
The Patients Association (UK)
The Pharmaceutical Security Institute (PSI)
www.visiongain.com
Contents ThermoFisher Scientific
TruTag Technologies
United Nations
University of South Dakota
UPM
UPM Kymmene
UPM Raflatac
UPM Rafsec z
US Center for Safe Internet Pharmacies (CSIP).
US Food and Drugs Agency (FDA)
US Pharmacopeial Convention (USP)
Visa
Vocollect Inc
Voxtel
Webscan
World Customs Organization
World Health Organization (WHO)
World Intellectual Property Organization (WIPO)
Zebra Technologies
Page 48
www.visiongain.com
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2014-2024
Passive RFID tags operate without a separate external power source and obtain operating power
generated from the reader. Passive tags are consequently much lighter than active tags, less
expensive, and offer a virtually unlimited operational lifetime. The trade off is that they have shorter
read ranges than active tags and require a higher-powered reader. Read-only tags are typically
passive and are programmed with a unique set of data (usually 32 to 128 bits) that cannot be
modified. Read-only tags most often operate as a licence plate into a database, in the same way
as linear barcodes reference a database containing modifiable product-specific information.
Figure 3.3 RFID Anti-counterfeiting Technologies: Drivers and Restraints, 2014-2024
The significant advantage of all types of RFID systems is the fact that authentication can be done
remotely as the technology does not require contact between reader and tag (Figure 3.3). Tags
can be read through a variety of substances such as snow, fog, ice, paint, dirt and other visually
and environmentally challenging conditions, where barcodes or other optically read technologies
would be useless. RFID tags can also be read in challenging circumstances at high speeds, in
most cases responding in less than 100 milliseconds. The read/write capability of an active RFID
system is also a significant advantage in interactive applications such as work-in-process or
maintenance tracking. Although it is a costlier technology (compared with barcodes), RFID has
become indispensable for a wide range of automated data collection and identification applications.
Table 3.4 summarises the leading global manufacturers of RFID tags.
Source: Visiongain 2013
• Supply chain tracking capabilities, now promoted by many regulatory authorities
• High level of security against
duplication • Tags can be read at distance
• Wireless capabilities means identification is possible without the need to physically see the tag
Drivers Restraints
• RFID tags may contain personal
information – potential for exposure of personal information
• Generally a high cost technology • Requirement for specialized
readers • Reliability, radio waves are
deflected or impeded by certain materials interfering with signals
Page 81
www.visiongain.com
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2014-2024
Table 4.16 Zebra Technologies: Product Groups and Descriptions, 2013
Technology Sector Description
For UHF RFID and HF RFID in the supply chain and for other applications
Encoded smart labels are printable labels embedded with an ultra-thin radio frequency transponder. Information encoded in these transponders can then be read and modified by a radio frequency reader. These labels eliminate the need of a visual ID of a barcode, as the ID signal is transmitted by radio frequency
Falls under the branch of location solutions, software and hardware are used to locate, track, manage, and improve operational functions
Zebra’s location solutions include asset tags, call tags, sensors, exciters and application software.
Active RFID products include, DartTag, WhereTag and WhereCall, incorporating various Real Time Locating System (RTLS) technologies based on ultra-wide band (UWB), WhereNet and Wi-Fi active RFID
Thermal barcode technology
Barcode printers with thermal-transfer and direct thermal technology produce accurate, high-quality images.
Passive RFID
Active RFID
The company operates within two branches – printing operations and location solutions. Within
these branches the company’s product range consists of direct thermal and thermal transfer label
and receipt printers, passive radio frequency identification (RFID) printer/encoders and dye
sublimation card printers. They also sell specialty supplies consisting of self-adhesive labels,
thermal transfer ribbons, thermal print-heads, batteries and other accessories, including software
for label design and printer network management. Some of the technology branches and their
applications are detailed in Table 4.16.
It is difficult to estimate the company’s contribution to the pharmaceutical anti-counterfeiting sector
because operations are spread over a range of industries. However, it is clear that Zebra
Technologies is an industry leader in printing solutions to identify, authenticate, track-and-trace
products. The company’s revenue in 2012 was $996.2m, which represents an increase of 1.3%
from the previous year (Table 4.17 and Figure 4.8).
Source: Zebra Technologies 2013, Visiongain 2013
Page 99
www.visiongain.com
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2014-2024
Table 5.9 Holograms/OVD: Revenue Forecast ($m, AGR%, CAGR%), 2012-2024
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Hologram/OVD ($m) 80.7 85.5 90.6 97.9 105.7 113.1 121.0 127.1 133.4 140.1 148.5 155.9 162.2Annual Growth (%) 6 6 8 8 7 7 5 5 5 6 5 4CAGR (% 2012-2017 & 2017-2024) 7.0 5.3CAGR (% 2012-2024) 6.0
Figure 5.11 Holograms/OVD: Revenue Forecast ($m), 2012-2024
Holograms and optically variable devices fall into the category of overt technologies. Although they
offer a relatively easy platform of anti-counterfeiting technology to implement – low cost and ease
in which they can be applied, in recent years the risk of imitation has risen. Visiongain believes that
potential security breaches and the strong growth of track-and-trace technologies (traditionally not
holograms/OVD) will ultimately slow the growth of hologram/OVD market and reduce its market
share. However, overall the hologram market will continue to see slow growth. Like most other
sub-markets, growth in the pharmaceutical holograms market will be driven by pharmaceutical
80.7
85.5 90.6
97.9 105.7
113.1 121.0
127.1 133.4
140.1 148.5
155.9 162.2
0
20
40
60
80
100
120
140
160
180
2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Rev
enue
($m
)
Year
Source: Visiongain 2013
Source: Visiongain 2013
Page 155
www.visiongain.com
Pharmaceutical Anti-counterfeiting Technologies: Market Analysis 2014-2024
8. Expert Opinions
8.1 Interview with Dr Fred Jordan, Chief Executive Officer, AlpVision In October 2013, visiongain interviewed Dr Fred Jordan (FJ), the chief executive officer of
AlpVision. Topics discussed include AlpVision’s key technologies and the advancements in anti-
counterfeiting technologies, the increasing sophistication of counterfeiting criminals, and the main
barriers and threats facing the implementation of anti-counterfeiting technologies.
We thank Dr Jordan for his time and opinion.
8.1.1 Current State of Counterfeiting in the Pharmaceutical Industry Visiongain: How severe would you say the counterfeiting situation is within the pharmaceutical
industry, and how do you see this changing in the next decade?
FJ: Judging as a technology provider based on the number of requests we get from the
pharmaceutical industry, if you take the top 50 pharmaceutical companies, I don’t know of any of
these companies who have absolutely no anti-counterfeiting efforts; so all of them are doing
something at some level. There are some exceptions for pharma companies who are only
manufacturing generics. Looking at the interests of these companies gives an extent of the severity
of the problem.
Visiongain: Based on the information you have, where in the globe do you think the biggest
counterfeiting threats lie?
FJ: I don’t know where the biggest threat is, but what I know is from which companies we get the
most requests. These are mainly European and US based companies.
8.1.2 AlpVison’s Key Technologies and Strategies for Combating
Counterfeiters Visiongain: Could you give us an insight into AlpVision’s key technologies, especially those
geared towards combating pharmaceutical anti-counterfeiting?
FJ: Firstly, all the technologies that we have are dedicated to combating counterfeiting. We have
two technologies: one is a printed technology which is appropriate for labels and packages. The
other technology is for moulded plastic like caps, bottles, syringes and other moulded items. These
are both used in the pharma field.